X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
onCARlytics (CF33-CD19) is a novel CD19 oncolytic virotherapy drug candidate, which is being evaluated for the treatment of patients with advanced solid tumors.
Lead Product(s): CF33-CD19,Blinatumomab
Therapeutic Area: Oncology Product Name: onCARlytics
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel, a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer.
Lead Product(s): Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MaxCyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
Details:
The collaboration aims to evaluate Imugene's allogeneic CAR T, azer-cel, in combination with NIT's proprietary immune T cell amplifier "Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.
Lead Product(s): Azercabtagene Zapreleucel,Efineptakin Alfa
Therapeutic Area: Oncology Product Name: Azer-Cel
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: NeoImmuneTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 11, 2023
Details:
Imugene gains global rights to PBCAR0191 (azercabtagene zapreleucel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing trial for azer-cel in the large B-cell lymphoma and has an option to develop up to three other cancer research programs.
Lead Product(s): Azercabtagene Zapreleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Precision BioSciences
Deal Size: $662.0 million Upfront Cash: $29.0 million
Deal Type: Licensing Agreement August 15, 2023
Details:
The collaboration aims to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
Lead Product(s): Oncolytic Virus Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: RenovoRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 20, 2023
Details:
onCARlytics (CF33-CD19, HOV4) is a live, attenuated oncolytic orthopox (vaccinia) virus engineered to encode a truncated human CD19 transgene, resulting in expression of de novo CD19 at the tumour cell surface before virus-mediated tumour cell lysis.
Lead Product(s): CF33-CD19,Blinatumomab
Therapeutic Area: Oncology Product Name: onCARlytics
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
City of Hope exclusively licensed patent rights covering Vaxina (CF33) to Imugene Limited, a company developing novel therapies that activate the immune system against cancer. Imugene has given CF33-hNIS the name Vaxinia.
Lead Product(s): CF33-hNIS,Pembrolizumab
Therapeutic Area: Oncology Product Name: Vaxina
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: City of Hope
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
Imugene in collaboration with MSD, initiated Phase 2 clinical trial designed to assess the safety of HER-Vaxx, which has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer.
Lead Product(s): HER-Vaxx,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMU-131
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2022
Details:
Under the terms of the agreement, Imugene will be the sponsor of the study for IMU-131 and will fund the clinical study from existing budgets and resources. Merck KGaA, Darmstadt, Germany and Pfizer will provide avelumab for the duration of the study.
Lead Product(s): HER-Vaxx,Avelumab
Therapeutic Area: Oncology Product Name: IMU-131
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2021
Details:
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived investigational T-cell therapy, CyCART-19.
Lead Product(s): CF33-CD19 Oncolytic Virus,CyCART-19
Therapeutic Area: Oncology Product Name: onCARlytics
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Celularity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
